Journal
MOLECULAR ONCOLOGY
Volume 15, Issue 11, Pages 2958-2968Publisher
WILEY
DOI: 10.1002/1878-0261.13082
Keywords
abscopal response; immunotherapy; non-small cell lung cancer; radiotherapy; T cell receptor sequencing
Categories
Funding
- Norwegian Cancer Society [190269-2017]
Ask authors/readers for more resources
By sequencing T cell receptors in patients with stage IV non-small cell lung cancer receiving a combination of radiotherapy and immunotherapy, it was found that responders showed increased TCR clone expansion and the emergence of new high abundance clones, which may be more related to radiotherapy than immune checkpoint blockade.
Previous studies have indicated a synergistic effect between radiotherapy and immunotherapy. A better understanding of how this combination affects the immune system can help to clarify its role in the treatment of metastatic cancer. We performed T cell receptor (TCR) sequencing on 46 sequentially collected samples from 15 patients with stage IV non-small cell lung cancer, receiving stereotactic body radiotherapy combined with a programmed cell death ligand-1 (PD-L1) inhibitor. TCR repertoire diversity was assessed using Renyi diversity curves and the Shannon diversity index. TCR clones were tracked over time. We found decreasing or stable diversity in the best responders, and an increase in diversity at progression in patients with an initial response. Expansion of TCR clones was more often seen in responders. Several patients also developed new clones of high abundance. This seemed to be more related to radiotherapy than to immune checkpoint blockade. In summary, we observed similar dynamics in the TCR repertoire as have been described with immunotherapy alone. In addition, the occurrence of new unique clones of high abundance after radiotherapy may indicate that radiotherapy functions as a personalized cancer vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available